Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients

NCT04372277 is registered in ClinicalTrials.gov with Psoriasis Treatment Center of Central New Jersey as lead sponsor.

NCT NCT04372277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04372277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Phase
Phase 4
Overall status
Recruiting
Start date
April 28, 2020
Completion date
March 30, 2021
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis